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Edited by Gerrit van MeerAbstract The transporter associated with antigen processing
(TAP) is a key factor of the major histocompatibility complex
(MHC) class I antigen presentation pathway. This ABC trans-
porter translocates peptides derived mainly from proteasomal
degradation from the cytosol into the ER lumen for loading onto
MHC class I molecules. Manifold mechanisms have evolved to
regulate TAP activity. During infection, TAP expression is
upregulated by interferon-c. Furthermore, the assembly and sta-
bility of the transport complex is promoted by various auxiliary
factors. However, tumors and viruses have developed sophisti-
cated strategies to escape the immune surveillance by suppress-
ing TAP function. The activity of TAP can be impaired on the
transcriptional or translational level, by enhanced degradation
or by inhibition of peptide translocation. In this review, we brieﬂy
summarize existing data concerning the regulation of the TAP
complex.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The transporter associated with antigen processing (TAP) is
a central component in the major histocompatibility complex
(MHC) class I dependent antigen presentation pathway.
TAP translocates peptides derived mainly from proteasomal
degradation from the cytosol into the lumen of the endoplas-
mic reticulum (ER), where these peptides are loaded onto
MHC class I molecules (Fig. 1). Stable peptide-MHC com-
plexes are transported to the cell surface to present their anti-Abbreviations: ABC, ATP-binding cassette; Ad, adenovirus; BHV,
bovine herpes virus; EGFP, enhanced green ﬂuorescent protein; ER,
endoplasmic reticulum; HPV, human papillomavirus; HSV, herpes
simplex virus; ICP47, infected cell protein 47; IFN-c, interferon-c;
MHC, major histocompatibility complex; NBD, nucleotide-binding
domain; PLC, peptide-loading complex; TAP, transporter associated
with antigen processing; TMD, transmembrane domain; UL49.5, un-
ique long region protein 49.5; US6, unique short region protein 6; vhs,
virion host shut-oﬀ; wt, wild-type
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doi:10.1016/j.febslet.2005.11.048genic cargo to CD8+-cytotoxic T-lymphocytes. The
recognition of viral or tumor antigens leads to an eﬃcient elim-
ination of the infected or malignant cell.
TAP belongs to the family of ATP-binding cassette (ABC)
transporters, which translocate a large variety of substrates
across membranes driven by ATP hydrolysis [1–3]. Human
TAP forms a heterodimer consisting of TAP1 (748 aa) and
TAP2 (686 aa) [4]. Both subunits are essential and suﬃcient
for peptide transport [5–7]. TAP is localized in the ER and
cis-Golgi [8]. Each subunit contains a transmembrane
domain (TMD), followed by a cytosolic nucleotide-binding
domain (NBD) (Fig. 2). The TMDs comprise the peptide
binding pocket and the translocation pathway for the
substrate. From hydrophobicity analysis and sequence align-
ment with P-glycoprotein, 10 and 9 transmembrane helices
have been predicted for TAP1 and TAP2, respectively [9].
The peptide-binding pocket is located to a region enclosing
the last cytosolic loop and a stretch of 15 residues following
the last transmembrane helix of both subunits [10]. Remark-
ably, TAP1 and TAP2 lacking the ﬁrst predicated four and
three transmembrane helices, respectively, are targeted to the
ER membrane and assemble into a fully functional heterodi-
meric transport complex, demonstrating that the extra N-ter-
minal regions (N-domains) of both subunits are not required
for peptide binding and transport [11,12]. These N-terminal
regions have been identiﬁed to be essential for tapasin bind-
ing and the assembly of the peptide-loading complex (see be-
low) [11]. The NBDs containing the highly conserved
Walker A/B motifs and the C-loop (ABC-signature) energize
peptide transport by ATP binding and hydrolysis.
The transport cycle is a multi-step process composed of
ATP and peptide binding, ATP hydrolysis and peptide trans-
location. Peptide binding follows a two step reaction with a
fast association preceding a slow conformational rearrange-
ment, which comprises one-fourth of all residues of TAP
[13,14]. A second conformational change seems to occur after
ATP binding, since the lateral membrane mobility of TAP
decreases drastically in the presence of peptide and ATP
[15]. TAP binds and transports most eﬃciently peptides with
a length of 8–16 and 8–12 amino acids, respectively [16,17].
The peptide speciﬁcity of TAP is restricted to the three N-ter-
minal residues and the C-terminal residue [18]. The speciﬁcity
for the C-terminal residue is very similar between the TAP
complex, immuno-proteasomes, and MHC class I molecules,
suggesting a co-evolution of these factors. However, the
length of the peptides as well as the speciﬁcity for the N-
terminal residue are distinct between TAP, the proteasomeblished by Elsevier B.V. All rights reserved.
Fig. 1. Antigen presentation pathway via MHC class I molecules. The MHC I heavy chain is co-translationally translocated into the ER, where it
folds and assembles with b2-microglobulin assisted by the immunoglobulin binding protein (BiP) and calnexin. Subsequently, MHC class I molecules
are recruited into a macromolecular peptide-loading complex (PLC) composed of calreticulin, ERp57, tapasin, TAP1 and TAP2. Peptides derived
mainly by proteasomal degradation in the cytosol are translocated by TAP into the lumen of the ER, where they are loaded onto pre-assembled
MHC class I molecules. Kinetically stable peptide-MHC complexes can escape the ER quality control and are transported via the Golgi to the cell
surface. Binding of T-cell receptor and CD8 co-receptor to trimeric MHC class I molecules triggers the killing of the target cell (adapted from [99]).
Fig. 2. Schematic model of the TAP complex. TAP forms a heterodimer composed of TAP1 and TAP2. Each subunit comprises an N-terminal
transmembrane domain and a C-terminal, cytosolic NBD (red). The transmembrane domain can be subdivided into a six helices containing core
domain and an NH2-terminal extension of four and three helices for TAP1 and TAP2, respectively. Beside the translocation pathway, the TMDs also
form the peptide-binding region (orange).
R. Abele, R. Tampe´ / FEBS Letters 580 (2006) 1156–1163 1157and MHC class I molecules. Peptides transported by TAP are
subsequently trimmed by amino exopeptidases in the ER [19–
22]. The sequence in between both anchor regions, which isrecognized by the T-cell receptor, is highly divers in respect
of TAP and MHC class I binding. This kind of clustered pro-
miscuity ensures that one TAP complex in combination with
1158 R. Abele, R. Tampe´ / FEBS Letters 580 (2006) 1156–1163a limited set of MHC class I alleles can oﬀer an almost
unlimited number of peptides to protect the organism against
intracellular pathogens and malignant transformation.
Peptides and ATP bind independently from each other to
TAP [16,17,23]. However, ATP hydrolysis is directly coupled
with peptide transport, since peptide binding correlates withFig. 3. Modulation of TAP function by viral factors. Upper panel: The struct
a model. ERp57 is covalently linked to tapasin via a disulﬁde bond (C95 of ta
control, calreticulin recognizes the N-core glycosylation of the MHC I heavy
only one of four TAP-associated sub-complexes (tapasin, MHC heavy chain,
E3 disturbs the interaction of MHC class I molecules with the pre-assembled T
MHC class I. Middle panel: The mK3 protein of murine c-herpesvirus-68 b
proteasomal degradation. The interaction of UL49.5 of the bovine herpes
transport-incompetent conformation, in which binding of ATP and peptide i
peptide binding from the cytosolic site of TAP. The association of US6 of t
TAP blocks ATP binding to the cytosolic NBD.ATPase activity [24]. In this process, a quality control exists,
since peptides with bulky side chains, which bind to but are
not transported by TAP, do not induce ATP hydrolysis.
Although both TAP subunits show an asymmetric functional
behavior, both of them are involved in energizing peptide
transport in a peptide-dependent manner [25,26].ural organization of the peptide-loading complex (PLC) is illustrated as
pasin to the CxxC motif of the oxidoreductase). Within the ER quality
chain (hc) and forms additional contacts with ERp57. For simplicity,
b2m, ERp57 and calreticulin) is shown. The E19 protein of adenovirus
AP–tapasin–ERp57 complex which impairs eﬃcient peptide loading of
inds directly to TAP and induces polyubiquitylation and subsequently
virus drives TAP to proteasomal degradation and arrests TAP in a
s not aﬀected. Lower panel: ICP47 of the herpes simplex virus inhibits
he human cytomegalovirus to the ER-luminal transmembrane core of
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TAP alone is suﬃcient for peptide translocation into the
ER lumen [7]. However, within the pathway of MHC class
I antigen processing, TAP is part of the multi-component
peptide-loading complex (PLC) (Figs. 1 and 3). This macro-
molecular complex is composed of one TAP heterodimer,
together with four tapasin and four MHC class I molecules
[27]. In addition, the lectin-like chaperones calreticulin and
calnexin, as well as the oxidoreductase ERp57 are associ-
ated. Calnexin, calreticulin and ERp57, are involved in the
maturation of MHC class I molecules. Additionally, calreti-
culin and ERp57 seem to assist in the optimization of pep-
tide loading onto MHC class I molecules [28–30]. The type I
transmembrane glycoprotein tapasin is an import factor of
the PLC and takes over several functions. It recruits the
other members of the PLC and connects the peptide trans-
location machine TAP to the peptide recipient MHC class
I [31–33]. The ER-luminal domain of tapasin binds to
MHC class I molecules with 1:1 stoichiometry [34,35]. This
interaction arrests MHC class I molecules loaded with low
aﬃnity peptides in the ER and ensures that only stable pep-
tide-MHC complexes can leave the ER [36]. Mechanistic de-
tails of how tapasin may facilitate and control peptide
binding to MHC class I molecules are still under discussion
[31,36,37]. The transmembrane helix of tapasin binds to the
N-domain of the TMDs of TAP subunits [11]. How tapasin
is associated with TAP is still puzzling, since the sequence
homology between the N-domains of TAP1 and TAP2 is
low in comparison to the rest of the protein. By increasing
its half-life, tapasin also stabilizes the TAP complex, result-
ing in a higher steady-state expression level of TAP and,
consequently, in a higher peptide transport rate [31,34,38].
This higher TAP level is due to an enhanced thermostability
of TAP in the presence of tapasin [39]. In tapasin deﬁcient
cells or cells expressing tapasin mutants, which are unable
to bind to TAP, the steady-state level of TAP is decreased
up to 100-fold [31].
Remarkably, the stability of the TAP complex does not
only rely on the interaction with tapasin, but also on the
interaction between both subunits. TAP1 alone can be ex-
pressed in TAP-deﬁcient T2 cells [40]. However, expression
of single TAP2 is not possible in this cell line. Furthermore,
expression of TAP2 is not observed in cells isolated from
Bare Lymphocytes Syndrome (BLS) type I patients lacking
the expression of TAP1 [41,42]. In the human melanoma
cell line buf1280, the TAP1 gene has a deletion mutation
at position 1489, leading to a frame shift and to an early
stop codon [43]. In these cells, mRNA of TAP1 and
TAP2 is present, however, neither TAP1 nor TAP2 can
be detected on the protein level. After introducing TAP1
wild-type (wt) in this cell line, normal TAP1 and TAP2
expression as well as peptide transport were restored. There-
fore, it appears that TAP2 is only stable in the presence of
TAP1 and single TAP2 is immediately degraded, possibly
by the proteasomal degradation pathway. Interestingly,
interferon-c, which is released during an infection, enhances
the expression of MHC class I heavy chain, b2m, tapasin,
TAP1, and TAP2. Promoter studies have shown that
TAP1 and TAP2 expression is regulated by partially diﬀer-
ent second messenger pathways and transcription factors
[44,45].3. Tumor escape by downregulation of TAP
A variety of ABC transporters are associated with cancer in
human. P-glycoprotein (ABCB1), the members of the multi-
drug resistance related protein (MRP) family, and ABCG2
transport anticancer drugs out of the cell, thus conferring tu-
mor cells resistance to chemotherapy. In addition, a surface
downregulation of MHC class I molecules on tumor cell is of-
ten observed, which facilitates these cells to escape immune sur-
veillance by suppression of the presentation of tumor-speciﬁc
antigens. A deﬁcient MHC class I cell surface expression can
be caused by defects in expression or function of factors of
the MHC class I antigen presentation pathway [46,47]. Fre-
quently, MHC class I downregulation is associated with TAP
malfunction [48]. The low or missing expression of TAP in tu-
mor cells impairs the formation of the peptide–MHC I com-
plexes in the ER. A higher frequency of deletion of the TAP
complex was observed in metastatic lesions than in primary le-
sions [48]. The importance of TAP in the immune surveillance
was highlighted in studies using a TAP1 deﬁcient mouse lung
carcinoma cell line (CMT.64). Restoration of TAP expression
by introducing exogenous TAP1 or by stimulation with inter-
feron-c (IFN-c) could correct the MHC class I deﬁciency
[49,50]. After TAP restoration, the tumor cell line was recog-
nized by cytotoxic T-cells in vitro. A decrease in tumor growth
and incidence was observed in vivo, by treating mice bearing
CMT.64 tumors with vaccinia or replication deﬁcient adenovi-
rus coding for TAP1 [51,52]. Diﬀerent mechanisms exist for the
downregulation of TAP in malignant cells. First, mutations in
the TAP1 gene were observed. One case is reported, where a
deletion of one nucleotide in the gene of TAP1 results in an
early stop codon. This truncated subunit cannot form a func-
tional TAP complex [43]. In a small cell lung cancer, an amino
acid exchange of TAP1 (R659Q) is found, which leads to a non-
functional TAP complex [53]. More often, the mRNA level of
TAP is decreased in malignant cells. In these cases, TAP expres-
sion can be restored by IFN-c treatment [54]. By chromatin
immunoprecipitation assays, the transcription rate of the
TAP1 gene was analyzed in diﬀerent murine carcinoma cell
lines [54]. By comparing the RNA polymerase II level at the
3 0 end of the coding region and the promoter region of the
TAP1 gene, it became obvious that the reduced transcriptional
rate is depending on impaired initiation of transcription. Sur-
prisingly, the TAP1 promoter shows no mutation in the
CMT.64 cell line. The analysis by TAP1-promoter driven
enhanced green ﬂuorescent protein (EGFP) expression demon-
strated that the promoter activity could be restored by IFN-c,
indicating that the promoter contains cis-acting elements, con-
ferring the relatively low activity in TAP1 deﬁcient cells. In
addition to cis-acting elements, trans-acting factors are likely
to be involved in regulating the TAP1 promoter activity, since
fusion of TAP1 deﬁcient carcinoma cells and wt ﬁbroblasts re-
stored TAP deﬁciency, at least partially. The TAP deﬁciency in
these carcinoma cell lines is not solely due to inhibition of tran-
scription, since a decreased but signiﬁcant promoter activity
could be detected. Again, in fusions of wt ﬁbroblasts with
TAP1 deﬁcient carcinoma cell lines, it could be shown that
the stability of especially TAP1 mRNA, but not of unrelated
mRNA, was decreased by an unknown mechanism.
Accelerated degradation of TAP1 mRNA was also found in
the human SK-MEL-19 melanoma cell line bearing a single-
nucleotide deletion at position 1489 [55]. Despite an active
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mRNA was not detectable. The mechanism of the degradation
is not known, but it is not aﬀected by nonsense-mediated
mRNA decay, because deletions of two additional nucleotides
in the region, which corrected the nonsense mutation, did not
restore TAP1 mRNA stability. In contrast to IFN-c, interleu-
kin-10 (IL-10) leads to downregulation of TAP and, subse-
quently, to reduced surface expression of MHC class I
molecules [56]. This fact may be of clinical relevance, since a
large number of human tumors secrete IL-10.4. Viral immune evasion by blocking TAP function
Many viruses, in particular slow replicating DNA viruses,
have developed elaborated mechanisms to evade immune
surveillance. These strategies prevent or delay immune recog-
nition of infected cells to enable the virus to replicate, colonize
the host, and transmit to other individuals. Frequently, the
viral factors block the function of the MHC class I antigen
presentation pathway and, hence, prevent the recognition
and elimination by cytotoxic T-lymphocytes [57,58]. Espe-
cially, persistent viruses rely on this mechanism to circumvent
T-cell recognition. In addition to MHC class I molecules,
TAP, and factors of the peptide-loading complex may be an
important target of the viral attack. Peptide transport into
the ER can be impaired by diﬀerent mechanisms, including
downregulation of TAP expression, enhanced degradation
mediated by viral factors, and blocking peptide transport by
direct interaction.
For cells infected with the oncogenic human papillomavirus
(HPV) type-18 and the adenovirus (Ad) type-12, downregula-
tion of TAP1 transcription was observed. The E7 protein of
HPV-18 and the E1A protein of Ad-12 repress the promoter
activity of tap1. Although both DNA viruses belong to diﬀer-
ent virus classes, the two factors are similar in structure and
function.
The virion host shut-oﬀ (vhs) mechanism, best studied on
the subfamily of Alphaherpesvirinae comprising herpes simplex
virus-1 (HSV1) and 2, varicella-zoster virus, and bovine her-
pesvirus (BHV), is a general strategy to suppress the expression
of host genes [59,60]. As a part of the infection virion, the vhs
protein accelerates the degradation of host mRNA and sup-
ports immune evasion in the early state of infection.
The mK3 protein of the murine c-herpesvirus-68 and the
E19 protein of the adenovirus E3 inhibit the antigen presenting
machinery by interacting with TAP without aﬀecting peptide
transport (Fig. 3). The mK3 protein is a type III transmem-
brane protein containing two transmembrane helices. mK3
binds via its C-terminal tail to tapasin and TAP [61,62], there-
by positioning the N-terminal RING-ﬁnger motif with an E3
ubiquitin ligase activity to the cytoplasmic tail of MHC class
I for subsequent ubiquitinylation and proteasomal degrada-
tion [63,64]. However, mK3 also induces in a MHC I indepen-
dent mechanism the degradation of TAP subunits and tapasin
[65,66]. For degradation of TAP, interaction of mK3 with
tapasin lacking the ER-luminal domain is suﬃcient; while,
for association of mK3 with and degradation of MHC class
I, the interaction with full-length tapasin is mandatory [66].
The ER-resident type I transmembrane glycoprotein E19
(19 kDa) protein of adenovirus E3 suppresses antigen presen-
tation by MHC class I molecules [67,68]. E3/19k binds via itsER-luminal domain to MHC class I molecules [69] and retains
these in the ER by a di-lysine motif localized in the cytosolic
domain of E3/19k [70]. Remarkably, E3/19k binds to TAP
and prevents assembly of MHC I-loading complex by disturb-
ing the MHC–tapasin interaction [71].
The human herpes simplex virus-1 and 2, the human
cytomegalovirus, and the bovine herpes virus code for factors
inhibiting TAP-dependent peptide transport into the ER
(Fig. 3). Strikingly, herpesviruses have developed distinct
strategies [58]. The immediate early gene product of HSV-1
(IE12; infected cell protein 47 (ICP47)) encodes an 88 amino
acids long cytosolic protein, which interferes with TAP func-
tion [72,73]. By binding with high aﬃnity to human TAP,
ICP47 inhibits peptide binding to and thereby ATP hydrolysis
of TAP [24,74,75]. However, ICP47 does not only compete
with peptide binding, but also induces a conformational
change of TAP, as shown by chemical cross-linking [76].
ICP47 is highly species speciﬁc, since it inhibits with high aﬃn-
ity peptide binding to human TAP (IC50 = 50 nM), but not to
TAP from mice, rabbit or guinea pig [74,75,77,78]. The active
domain of ICP47 was determined by truncation studies to
residues 3–34 [13]. The function of the C-terminal domain of
ICP47 is not yet understood. The active domain undergoes a
conformational change during membrane association. In
aqueous solution, ICP47 is unstructured, whereas it adopts
an a-helical conformation after membrane association [79].
As resolved by solution NMR in membrane mimicking envi-
ronment, the active domain of ICP47 contains two a-helices
connected by a ﬂexible loop [80]. By an alanine scanning
approach and site-directed mutagenesis, residues critical for
TAP inhibition were deciphered [13,81]. These residues are
clustered in three regions, which cover both a-helices and the
connecting loop. Which region of TAP interacts with ICP47
is, however, still a puzzling question.
The human cytomegalovirus has evolved several strategies to
downregulate MHC class I surface expression [82,83]. One
mechanism is the inhibition of peptide transport by the
23 kDa type I transmembrane glycoprotein unique short re-
gion protein 6 (US6) of the unique short (US) region [84–
86]. US6 inhibits TAP via its ER-luminal domain (Fig. 3)
[84]. Binding of US6 to TAP in the ER lumen prevents ATP
binding to the NBDs localized in the cytosol, whereas peptide
binding is not aﬀected by US6 [87,88]. US6 seems to induce a
long ranging conformational rearrangement in TAP. Like
ICP47, US6 prevents conformational rearrangements induced
by peptide binding [76,87]. TAP denatures rapidly in vitro at
physiological temperature, which is reﬂected in decreased pep-
tide binding and transport, as well as decreased immunodetec-
tion by antibodies [89]. The stability is drastically increased in
the presence of ADP or ATP. US6 seems to induce similar
structural eﬀects as nucleotides, since it also stabilizes TAP
against thermal denaturation [87]. By using the isolated, solu-
ble ER-luminal domain of US6, an IC50 value of 1 lM for
TAP inhibition was determined [88]. The binding sites of
US6 are mapped to the inner 2 · 6 transmembrane helices,
as N-terminal truncated TAP complexes are inhibited by
US6 [11].
The bovine herpesvirus is a member of the subfamily of the
Alphaherpesvirinae persisting in its host for life after a short
acute phase of infection. Interestingly, BHV can also infect hu-
man cells and interferes with antigen processing and presenta-
tion in human cells [90]. Gene products from the early phase of
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[91,92]. In a proteomic approach, the viral factor unique long
region protein 49.5 (UL49.5) was identiﬁed to be associated
with human TAP in the human melanoma cell line Mel JuSo
[90]. The type I transmembrane glycoprotein (9 kDa)
UL49.5, also known as glycoprotein N (gN) [93], is found as
monomer, homodimer and heterodimer with the viral glyco-
protein M (gM) in infected cells and virion envelopes [94,95].
This factor has two independent mechanisms to downregulate
peptide supply into the ER lumen (Fig. 3). The association of
UL49.5 with TAP induces the proteasomal degradation of
TAP as well as UL49.5. For this process, the C-terminal,
cytoplasmic tail of UL49.5 is essential. Additionally, UL49.5
arrests TAP in a peptide translocation-incompetent conforma-
tion, in which peptide and ATP binding are not aﬀected. By
tagging TAP1 C-terminally with GFP, the UL49.5 mediated
degradation, but neither the association of nor the transport
inhibition by UL49.5 could be inhibited. Although homo-
logues of UL49.5 are found in genomes of all herpesviruses se-
quenced to date [96], only UL49.5 homologues from
pseudorabies virus and from equine herpesvirus-1, but not
from HSV1 and HSV2, Epstein–Barr virus and varicella-zoster
virus interfered with TAP function [90].
Obviously, further viral strategies to inhibit TAP function
do exist, since cells infected by human immune-deﬁciency virus
type 1 (HIV-1) or Epstein–Barr virus (EBV) show impaired
peptide transport into the ER lumen [97,98]. However, the fac-
tors and molecular mechanisms of TAP mechanism still have
to be elucidated.
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